Veru Dirección
Dirección controles de criterios 3/4
El CEO de Veru es Mitch Steiner , nombrado en Oct 2016, tiene una permanencia de 8.08 años. compensación anual total es $4.71M, compuesta por 18.4% salario y 81.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.84% de las acciones de la empresa, por valor de $5.20M. La antigüedad media del equipo directivo y de la junta directiva es de 6.2 años y 3.9 años, respectivamente.
Información clave
Mitch Steiner
Chief Executive Officer (CEO)
US$4.7m
Compensación total
| Porcentaje del salario del CEO | 18.4% |
| Permanencia del CEO | 8.1yrs |
| Participación del CEO | 4.8% |
| Permanencia media de la dirección | 6.2yrs |
| Promedio de permanencia en la Junta Directiva | 3.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Veru (NASDAQ:VERU) A Risky Investment?
Aug 07
What Veru Inc.'s (NASDAQ:VERU) 28% Share Price Gain Is Not Telling You
Jul 17Veru Inc.'s (NASDAQ:VERU) 35% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
May 31The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Jan 09Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
Aug 16Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Apr 17Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
Feb 14Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Jan 13Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically
Nov 13Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict
Oct 17Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?
Sep 26Veru FDA AdCom meeting for COVID-19 therapy postponed
Sep 19Veru: A Good Combination Of A Stable Business And Growth Opportunities
Sep 13Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy
Sep 07Veru sheds 13% to end rally as director sells shares
Aug 18Veru Q3 2022 Earnings Preview
Aug 10Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Aug 03Veru eligible for expedited review in U.K. for COVID-19 therapy
Jul 25Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | n/a | n/a | -US$63m |
| Sep 30 2023 | US$5m | US$866k | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$126m |
| Mar 31 2023 | n/a | n/a | -US$136m |
| Dec 31 2022 | n/a | n/a | -US$116m |
| Sep 30 2022 | US$6m | US$761k | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | n/a | n/a | -US$16m |
| Sep 30 2021 | US$2m | US$618k | US$7m |
| Jun 30 2021 | n/a | n/a | -US$144k |
| Mar 31 2021 | n/a | n/a | -US$476k |
| Dec 31 2020 | n/a | n/a | US$2m |
| Sep 30 2020 | US$1m | US$502k | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$10m |
| Dec 31 2019 | n/a | n/a | -US$13m |
| Sep 30 2019 | US$800k | US$392k | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | n/a | n/a | -US$22m |
| Sep 30 2018 | US$740k | US$383k | -US$24m |
Compensación vs. Mercado: La compensación total de Mitch($USD4.71M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD653.78K).
Compensación vs. Ingresos: La compensación de Mitch ha sido consistente con los resultados de la empresa en el último año.
CEO
Mitch Steiner (63 yo)
8.1yrs
Permanencia
US$4,714,041
Compensación
Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 8.1yrs | US$4.71m | 4.84% $ 5.2m | |
| Vice Chairman & Chief Corporate Officer | 8.1yrs | sin datos | 5.47% $ 5.9m | |
| CFO & Chief Administrative Officer | 6.9yrs | US$1.55m | 0.066% $ 70.6k | |
| Chief Scientific Officer | 6.2yrs | US$1.69m | 0.0034% $ 3.7k | |
| Executive Director of Investor Relations & Corporate Communications | 5.6yrs | sin datos | sin datos | |
| Executive VP | 3.7yrs | sin datos | sin datos | |
| Executive Vice President of Corporate Development | 7.8yrs | sin datos | sin datos | |
| Executive Vice President of FC2 Global Operations | no data | US$193.01k | sin datos | |
| Executive VP & Deputy General Counsel | 3.8yrs | sin datos | sin datos | |
| Executive Vice President of Global Clinical Operations | 6.6yrs | sin datos | sin datos | |
| Executive Vice President of Quality & Regulatory Affairs | 5.8yrs | sin datos | sin datos | |
| Executive VP and GM of UK | 2.3yrs | sin datos | sin datos |
6.2yrs
Permanencia media
62.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VERU es experimentado (6.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 8.1yrs | US$4.71m | 4.84% $ 5.2m | |
| Vice Chairman & Chief Corporate Officer | 8.1yrs | sin datos | 5.47% $ 5.9m | |
| Chief Medical Advisor & Member of the Scientific Advisory | less than a year | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | 1.8yrs | sin datos | sin datos | |
| Board Observer | 8.1yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 1.4yrs | sin datos | sin datos | |
| Independent Director | 6.7yrs | US$875.93k | 0.068% $ 73.4k | |
| Independent Director | 3.5yrs | US$835.75k | 0.0067% $ 7.2k | |
| Member of Scientific Advisory Board | less than a year | sin datos | sin datos | |
| Independent Director | 8.1yrs | US$795.57k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$755.39k | 0.010% $ 10.8k | |
| Member of the Scientific Advisory Board | 1.4yrs | sin datos | sin datos |
3.9yrs
Permanencia media
66yo
Promedio de edad
Junta con experiencia: La junta directiva de VERU se considera experimentada (3.9 años de antigüedad promedio).